Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 7 recruiting now early-phase tilt small index

Liver Fibrosis: early-phase trial registry

7 of 12 indexed Liver Fibrosis trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,429 of 28,707 conditions by registered trial count.

12 US clinical trials · 7 currently recruiting · #1,429 of 28,707 conditions by registered trial count

Liver Fibrosis: 12 US clinical trials tracked, 7 recruiting.

Liver Fibrosis is the subject of 12 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Arunark Kolipaka, running 1 of these trials.

Enrollment posture brief

Registry condition liver-fibrosis

OPEN 7 | RECR 58% | LATE 2 | EARLY 4 | RANK #1429 | SPON 1

Nearest open-share peer: Anterior Cruciate Ligament Reconstruction (58% recruiting · 12 trials)

Liver Fibrosis (this)58%Acute Myeloid Leukemia in Re41.7%Adenocarcinoma of the Rectum41.7%Adherence, Patient16.7%Accelerated Phase Chronic My0%
Open-enrollment share among volume-matched conditions near Liver Fibrosis

Liver Fibrosis lists 7 open slots (58% of 12 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Liver Fibrosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Liver Fibrosis is recruiting above its size-band peers.

    7 of 12 indexed trials (58.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Liver Fibrosis trials is spread across many organizations.

    Arunark Kolipaka accounts for 1 of 12 trials (8.3%). 12 distinct sponsors appear on at least one study for this condition label.

  3. Typical Liver Fibrosis enrolment sits around 128 participants.

    Median target enrolment is 128 among the 12 trials that report a genuine target (sentinel values excluded). 4 of those (33.3%) plan for fewer than 100 participants.

  4. Liver Fibrosis splits between interventional and observational designs.

    8 interventional and 4 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22Phase 31Phase 41

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 3 1,800 participants

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Boehringer Ingelheim

NCT06632444

RECRUITING 1,000 participants

Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues

Arunark Kolipaka

NCT01757730

RECRUITING 400 participants

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

Foundation for the National Institutes of Health

NCT07122700

RECRUITING NA 132 participants

Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial

Pichamol Jirapinyo, MD, MPH

NCT06138821

RECRUITING Phase 2 128 participants

Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans

VA Office of Research and Development

NCT05526144

RECRUITING Phase 4 120 participants

Fibrosis Lessens After Metabolic Surgery

Ali Aminian

NCT06374875

RECRUITING Phase 1 74 participants

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

PharmaIN

NCT05490888

COMPLETED NA 270 participants

Liver Fibrosis Evaluation Using Ultrasound Shear Wave Imaging

Mayo Clinic

NCT03637959

COMPLETED 127 participants

Liver Fibrosis in HIV-Infected Patients With Elevated Liver Enzymes on Antiretroviral Therapy

National Institute of Allergy and Infectious Diseases (NIAID)

NCT00326482

COMPLETED Phase 2 20 participants

Pilot Study of Simtuzumab in the Treatment of Liver Fibrosis

Gilead Sciences

NCT01452308

COMPLETED 17 participants

Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases

Baylor College of Medicine

NCT01988753

COMPLETED Phase 1 16 participants

Imaging of Pathologic Fibrosis Using 68Ga-FAP-2286

Thomas Hope

NCT05180162

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2
Phase 3 1
Phase 4 1

Named interventions

Most-linked intervention names on Liver Fibrosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Mechanical Vibrations with Ultrasound Shear Wave Imaging Device
1 trials
Simtuzumab Biological
1 trials
Survodutide Combination
1 trials
Positron Emission Tomography (PET) Procedure
1 trials
Synthroid Drug
1 trials
Incretin-Based Therapy Drug
1 trials
Metabolic surgery Procedure
1 trials
Lifestyle modification Behavioral
1 trials

US sites by state

Facility locations filed on Liver Fibrosis trials. A trial with sites in several states counts in each.

Ohio 4 trials
Texas 3 trials
Minnesota 3 trials
California 3 trials
Arizona 3 trials
West Virginia 1 trials
Pennsylvania 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Liver Fibrosis page

12 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Liver Fibrosis condition card totals 12 registered trials; most-linked intervention Mechanical Vibrations with Ultrasound Shear Wave Imaging; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.